Effects of the somatostatin analog lanreotide on the circulating levels of chromogranin-A, prostate-specific antigen, and insulin-like growth factor-1 in advanced prostate cancer patients.
about
Prognostic role of neuroendocrine differentiation in prostate cancer, putting together the pieces of the puzzle.New agonist- and antagonist-based treatment approaches for advanced prostate cancer.Neuroendocrine differentiation of prostate cancer: a review.Octreotide scintigraphy and Chromogranin A do not predict clinical response in patients with octreotide acetate-treated hormone-refractory prostate cancer.Possible involvement of prolactin in endocrine-resistant metastatic prostate cancer.Somatostatin analog lanreotide in the treatment of castration-resistant prostate cancer (CRPC)
P2860
Effects of the somatostatin analog lanreotide on the circulating levels of chromogranin-A, prostate-specific antigen, and insulin-like growth factor-1 in advanced prostate cancer patients.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Effects of the somatostatin an ...... nced prostate cancer patients.
@en
Effects of the somatostatin an ...... nced prostate cancer patients.
@nl
type
label
Effects of the somatostatin an ...... nced prostate cancer patients.
@en
Effects of the somatostatin an ...... nced prostate cancer patients.
@nl
prefLabel
Effects of the somatostatin an ...... nced prostate cancer patients.
@en
Effects of the somatostatin an ...... nced prostate cancer patients.
@nl
P2093
P2860
P356
P1433
P1476
Effects of the somatostatin an ...... nced prostate cancer patients.
@en
P2093
G Gorzegno
L Dogliotti
R Tarabuzzi
P2860
P304
P356
10.1002/PROS.1064
P577
2001-05-01T00:00:00Z